文献速递前列腺增生与排尿功能障碍泌尿系感染

男性难治性特发性逼尿肌过度活动的肉毒毒素A注射治疗

Onabotulinum toxin A Injections in Men With Refractory Idiopathic Detrusor Overactivity.
PubMed 文献 · Urology · 2018-09-26

男性生活质量评分显著改善,但改善幅度小于女性;清洁间歇自导尿和尿路感染发生率两性相似。

要点

  • 男性BTX-A治疗后生活质量评分显著改善,但改善幅度小于女性。
  • 男性清洁间歇自导尿需求42.6%,女性35.3%,差异无统计学意义。
  • 尿路感染率男性29.0%,女性27.0%,两组相似。

核心结论

  • 男性难治性OAB患者接受BTX-A后生活质量评分显著改善,但获益程度似乎低于女性。
  • 两性在清洁间歇自导尿需求和尿路感染率方面相似。

主要发现

  • 男性UDI-6评分下降4.2分(P=.00),IIQ-7评分下降6.0分(P=.00)。
  • 女性UDI-6评分下降6.0分(P=.00),IIQ-7评分下降11.1分(P=.00)。
  • 男性需清洁间歇自导尿46例(42.6%),女性107例(35.3%),P=.10。
  • 男性尿路感染36例(29.0%),女性86例(27.0%),P=.73。
  • 膀胱流出道梗阻指数和膀胱收缩力指数不能可靠预测清洁间歇自导尿需求。

关键数值与推荐

  • 男性难治性OAB患者BTX-A治疗后UDI-6下降4.2分,IIQ-7下降6.0分(P=.00)。
  • 女性UDI-6下降6.0分,IIQ-7下降11.1分(P=.00)。
  • 清洁间歇自导尿率男性42.6%,女性35.3%(P=.10);尿路感染率男性29.0%,女性27.0%(P=.73)。

临床怎么用

  • BTX-A可用于改善男性难治性特发性逼尿肌过度活动患者的生活质量,但需告知其获益可能小于女性。
  • 治疗前应告知清洁间歇自导尿和尿路感染风险,且尿动力学指标不能可靠预测清洁间歇自导尿需求。

局限性

  • 本研究为单中心回顾性分析,样本量有限,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To establish the effectiveness and safety profile of Onaboulinum toxin A (BTX-A) in men with idiopathic detrusor overactivity and compare with the outcomes observed in women. Several randomized trials have demonstrated the effectiveness of intradetrusor BTX-A injections in improving symptoms and quality of life in patients with overactive bladder (OAB) symptoms. Most trials however contained relatively few men or excluded men altogether. MATERIALS AND METHODS: Data patient undergoing BTX-A for refractory OAB with idiopathic detrusor overactivity on urodynamics were extracted from our center's prospectively maintained database. Incontinence impact questionnaire-7 and urogenital distress inventory-6 scores were collected at baseline and 4-12 weeks together with data regarding urinary retention requiring clean intermittent self-catheterization (CISC) and urinary tract infection (UTI). Urodynamic studies were assessed where available to see if voiding dysfunction and CISC were predictable. RESULTS: Sixty-five men received 133 BoNT-A treatments in the 15-year period representing 27.8% of those with refractory OAB. Baseline urogenital distress inventory-6 and incontinence impact questionnaire-7 fell by 4.2 (P = .00) and 6.0 (P = .00) points for men and by 6.0 (P = .00) and 11.1 (P = .00) for women, respectively. De novo CISC was required in 46 (42.6%) men and 107 (35.3%) women (P = .10). UTI was reported in 36 (29.0%) men and 86 (27.0%) women (P = .73). The bladder outflow obstruction index and the bladder contractility index did not reliably predict CISC requirement. CONCLUSION: Men with refractory OAB experience significant improvement in quality of life scores following BTX-A, though the benefit appears greater in women. The requirements for CISC and UTI rates were similar between sexes.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Faure Walker NA, Syed O, Malde S, et al. Onabotulinum toxin A Injections in Men With Refractory Idiopathic Detrusor Overactivity. Urology. 2018. PMID: 30266377. doi:10.1016/j.urology.2018.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。